Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18100454 | 1.00 | MEN1 (0.37) | MEN1KMT2ACYP2C9CYP3A4DHODH | |
| SCHEMBL17435694 | 1.00 | MEN1 (0.37) | MEN1KMT2ACYP2C9CYP3A4DHODH | |
| SCHEMBL17435696 | 1.00 | MEN1 (0.37) | MEN1KMT2ACYP2C9CYP3A4DHODH | |
| SCHEMBL17435512 | 1.00 | MEN1 (0.37) | MEN1KMT2ACYP2C9CYP3A4DHODH | |
| SCHEMBL19102744 | 0.94 | MEN1 (0.38) | MEN1KMT2ACYP2C9CYP3A4DHODH | |
| SCHEMBL17451844 | 0.91 | DHODH (0.43) | CYP2C9DHODHALDH1A1GAALMNA | |
| SCHEMBL17453185 | 0.91 | DHODH (0.43) | CYP2C9DHODHALDH1A1GAALMNA | |
| SCHEMBL17451845 | 0.89 | PLA2G2A (0.41) | MEN1KMT2ADHODHMAPTALDH1A1 | |
| SCHEMBL17453175 | 0.89 | PLA2G2A (0.41) | MEN1KMT2ADHODHMAPTALDH1A1 | |
| SCHEMBL17451846 | 0.89 | PLA2G2A (0.41) | MEN1KMT2ADHODHMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369426-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9403758-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160016895-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016895-A1 | ANTIBACTERIAL AGENTS | MRPL21, ABCB11, LSS | MEN1 2371/4885KMT2A 4840/4885CYP2C9 527/4885 |
| US-20170369426-A1 | ANTIBACTERIAL AGENTS | MRPL21, ABCB11, LSS | MEN1 2371/4885KMT2A 4840/4885CYP2C9 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.